Literature DB >> 25433505

Renal cell carcinoma and tumour thrombus in the inferior vena cava: clinical outcome of 98 consecutive patients and the prognostic value of preoperative parameters.

Christian Niedworok1, Bettina Dörrenhaus2, Frank Vom Dorp3, Jarowit Adam Piotrowski4, Stephan Tschirdewahn5, Tibor Szarvas6, Herbert Rübben7, Marcus Schenck8.   

Abstract

OBJECTIVES: To evaluate the outcome of patients after nephrectomy and removal of tumour thrombus and to assess the prognostic value of preoperative parameters. PATIENTS AND METHODS: Ninety-eight patients who were surgically treated between 2002 and 2011 were included. Patients' charts were reviewed, and patients with renal cell carcinoma (RCC) and concomitant tumour thrombus in the renal vein (RV) were compared with those with extended inferior vena cava (IVC) thrombus. Wilcoxon rank-sum test, Kaplan-Meier analysis and uni- and multivariate Cox regression analysis were used for statistical evaluation.
RESULTS: Follow-up was 36 months (20-122 months), and 5-year disease-specific survival (DSS) and overall survival were 68.4 and 54.1 %, respectively. Patients with extended thrombus (levels 2-4) had higher intraoperative transfusion rates of concentrated red cells (CRC) and fresh-frozen plasma (FFP) compared with patients with thrombus confined to the RV (CRC: 5.8 vs. 1.5, p < 0.0001; FFP: 2.3 vs. 0.4, p = 0.0032). Surgery time (190 vs. 107 min, p < 0.0001), duration of hospitalisation (16 vs. 11 days, p = 0.0269), serum phosphate (3.64 vs. 3.29 mmol/l, p = 0.0369) and CRP levels (6.7 vs. 4.4 mg/dl, p = 0.0194) as well as aPTT were increased (33.7 vs. 29.6 s, p = 0.0059) in extended thrombus disease. In multivariate analysis, the presence of distant metastasis (p = 0.03) and lymphovascular invasion (p = 0.001), high platelet counts (p = 0.001) and high serum potassium levels (p = 0.032) proved to be independent prognostic factors.
CONCLUSION: The surgical treatment of RCC with tumour thrombus in the RV or IVC has favourable results. Extended thrombus disease requires multidisciplinary approach. High serum potassium levels and platelet counts are associated with reduced DSS.

Entities:  

Keywords:  Kidney cancer; Platelets; Potassium; Prognostic parameters; Renal cell carcinoma; Tumour thrombus

Mesh:

Year:  2014        PMID: 25433505     DOI: 10.1007/s00345-014-1449-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  29 in total

1.  Impact of venous tumour thrombus consistency (solid vs friable) on cancer-specific survival in patients with renal cell carcinoma.

Authors:  Roberto Bertini; Marco Roscigno; Massimo Freschi; Elena Strada; Diego Angiolilli; Giovanni Petralia; Rayan Matloob; Francesco Sozzi; Umberto Capitanio; Luigi Filippo Da Pozzo; Renzo Colombo; Giorgio Guazzoni; Anna Cremonini; Francesco Montorsi; Patrizio Rigatti
Journal:  Eur Urol       Date:  2011-05-24       Impact factor: 20.096

2.  Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma.

Authors:  Marco Moschini; Nazareno Suardi; Federico Pellucchi; Lorenzo Rocchini; Giovanni La Croce; Umberto Capitanio; Alberto Briganti; Rocco Damiano; Francesco Montorsi; Renzo Colombo
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

3.  Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.

Authors:  Axel Haferkamp; Patrick J Bastian; Hildegard Jakobi; Maria Pritsch; Jesco Pfitzenmaier; Peter Albers; Peter Hallscheidt; Stefan C Müller; Markus Hohenfellner
Journal:  J Urol       Date:  2007-05       Impact factor: 7.450

Review 4.  Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer.

Authors:  M A Kuczyk; C Bokemeyer; G Köhn; C G Stief; S Machtens; M Truss; K Höfner; U Jonas
Journal:  Br J Urol       Date:  1997-07

5.  Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus.

Authors:  Erica H Lambert; Phillip M Pierorazio; Ahmad Shabsigh; Carl A Olsson; Mitchell C Benson; James M McKiernan
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

6.  Silencing the activity and proliferative properties of the human EagI Potassium Channel by RNA Interference.

Authors:  Claudia Weber; Fernanda Mello de Queiroz; Bryan R Downie; Arnt Suckow; Walter Stühmer; Luis A Pardo
Journal:  J Biol Chem       Date:  2006-03-14       Impact factor: 5.157

7.  Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi.

Authors:  Paul Sweeney; Christopher G Wood; Louis L Pisters; Joel W Slaton; Ara Vaporciyan; Mark Munsell; Scott Carpenter; Joe Putnam; Stephen G Swisher; Garret Walsh; David Swanson; Colin P N Dinney
Journal:  Urol Oncol       Date:  2003 Sep-Oct       Impact factor: 3.498

8.  Significance of platelet counts in patients who underwent surgical treatment for lung metastasis.

Authors:  Akinori Iwasaki; Wakako Hamanaka; Toshinori Harnada; Shinichi Maekawa; Sotarou Enatsu; Takayuki Shirakusa
Journal:  Int Surg       Date:  2007 Mar-Apr

9.  Prognostic factor for Korean patients with renal cell carcinoma and venous tumor thrombus extension: application of the new 2009 TNM staging system.

Authors:  Min Chul Cho; Jung Kwon Kim; Kyung Chul Moon; Hyeon Hoe Kim; Cheol Kwak
Journal:  Int Braz J Urol       Date:  2013 May-Jun       Impact factor: 1.541

10.  Renal carcinoma with supradiaphragmatic tumor thrombus: avoiding sternotomy and cardiopulmonary bypass.

Authors:  Gaetano Ciancio; Samir P Shirodkar; Mark S Soloway; Alan S Livingstone; Michael Barron; Tomas A Salerno
Journal:  Ann Thorac Surg       Date:  2010-02       Impact factor: 4.330

View more
  7 in total

1.  Fate of newly developed pulmonary embolism after surgery for renal cell carcinoma with vena cava thrombus.

Authors:  Sangjun Yoo; Sang Hoon Song; Heounjeong Go; Dalsan You; Cheryn Song; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn; In Gab Jeong
Journal:  Int Urol Nephrol       Date:  2017-04-11       Impact factor: 2.370

2.  Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method.

Authors:  Christian Niedworok; Frank vom Dorp; Stephan Tschirdewahn; Herbert Rübben; Henning Reis; Miklos Szucs; Tibor Szarvas
Journal:  Int Urol Nephrol       Date:  2016-01-02       Impact factor: 2.370

3.  The Contribution of MMP-7 Promoter Polymorphisms in Renal Cell Carcinoma.

Authors:  Cheng-Hsi Liao; Wen-Shin Chang; Pei-Shin Hu; Hsi-Chin Wu; Shih-Wei Hsu; Yen-Fang Liu; Shih-Ping Liu; Huey-Shan Hung; DA-Tian Bau; Chia-Wen Tsai
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

4.  Serum and tissue syndecan-1 levels in renal cell carcinoma.

Authors:  Christian Niedworok; Carsten Kempkensteffen; Andreas Eisenhardt; Stephan Tschirdewahn; Christian Rehme; Andrej Panic; Henning Reis; Hideo Baba; Peter Nyirády; Boris Hadaschik; Ilona Kovalszky; Tibor Szarvas
Journal:  Transl Androl Urol       Date:  2020-06

Review 5.  Clinical and Prognostic Effect of Plasma Fibrinogen in Renal Cell Carcinoma: A Meta-Analysis.

Authors:  Yuejun Tian; Mei Hong; Suoshi Jing; Xingchen Liu; Hanzhang Wang; Xinping Wang; Dharam Kaushik; Ronald Rodriguez; Zhiping Wang
Journal:  Biomed Res Int       Date:  2017-01-05       Impact factor: 3.411

6.  The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis.

Authors:  Haifeng Song; Guanyu Kuang; Zhenan Zhang; Binglei Ma; Jie Jin; Qian Zhang
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

7.  Significant Contribution of DNA Repair Human 8-Oxoguanine DNA N-Glycosylase 1 Genotypes to Renal Cell Carcinoma.

Authors:  Wen-Shin Chang; Te-Chun Shen; Jiuan-Miaw Liao; Yueh-Ting Tsai; Te-Chun Hsia; Hsi-Chin Wu; Chia-Wen Tsai; Da-Tian Bau
Journal:  Onco Targets Ther       Date:  2020-02-20       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.